Fabiola León-Velarde Selected Research

Iron

11/2014	Prevalence, clinical profile, iron status, and subject-specific traits for excessive erythrocytosis in andean adults living permanently at 3,825 meters above sea level.
1/2012	Regulation of hepcidin expression at high altitude.
1/2011	Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial.
10/2009	Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabiola León-Velarde Research Topics

Disease

21	Hypoxia (Hypoxemia) 11/2019 - 06/2003
10	Altitude Sickness (Mountain Sickness) 01/2020 - 01/2005
3	Polycythemia (Erythrocytosis) 03/2015 - 11/2014
3	Pulmonary Hypertension 10/2009 - 06/2003
2	Body Weight (Weight, Body) 01/2020 - 01/2009
2	Insulin Resistance 09/2018 - 01/2018
2	Hypertension (High Blood Pressure) 09/2018 - 01/2007
2	Weight Loss (Weight Reduction) 01/2018 - 09/2014
2	Iron Deficiencies 01/2012 - 10/2009
2	Hypertrophy 05/2010 - 06/2003
1	Cardiomegaly (Heart Hypertrophy) 11/2020
1	Pulmonary Arterial Hypertension 01/2019
1	Pulmonary edema of mountaineers 01/2018
1	Chronic Disease (Chronic Diseases) 03/2015
1	Isolated Systolic Hypertension 01/2009
1	Tachycardia (Tachyarrhythmias) 01/2007
1	Overweight 01/2007
1	Hypoventilation 12/2005
1	Apnea 12/2005

Drug/Important Bio-Agent (IBA)

5	Hemoglobins (Hemoglobin)IBA 01/2018 - 01/2005
4	Erythropoietin FDA Link 01/2020 - 01/2005
4	IronIBA 11/2014 - 10/2009
3	Erythropoietin Receptors (Erythropoietin Receptor)IBA 01/2016 - 01/2005
3	LipidsIBA 09/2014 - 01/2007
2	NADPH Oxidases (NAD(P)H oxidase)IBA 11/2020 - 01/2014
2	Insulin (Novolin)FDA Link 01/2020 - 01/2018
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2019 - 01/2014
2	Glucose (Dextrose)FDA LinkGeneric 09/2018 - 01/2018
2	Nitric Oxide Synthase (NO Synthase)IBA 09/2017 - 01/2014
2	N 30IBA 01/2009 - 01/2006
2	Acetazolamide (Diamox)FDA LinkGeneric 08/2008 - 12/2005
1	Protein Kinases (Protein Kinase)IBA 11/2020
1	NADP (NADPH)IBA 11/2020
1	A-factor (Streptomyces)IBA 01/2020
1	Arginine (L-Arginine)FDA Link 01/2019
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 01/2019
1	symmetric dimethylarginineIBA 01/2019
1	Triglycerides (Triacylglycerol)IBA 09/2018
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2018
1	antineoplaston A10 (A 10)IBA 01/2018
1	AMP-Activated Protein KinasesIBA 01/2018
1	omega-N-Methylarginine (NG Monomethyl L Arginine)IBA 09/2017
1	Proteins (Proteins, Gene)FDA Link 03/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2014
1	Superoxides (Superoxide)IBA 01/2014
1	3-nitrotyrosineIBA 01/2014
1	HepcidinsIBA 01/2012
1	Hormones (Hormone)IBA 01/2012
1	Vasoconstrictor AgentsIBA 05/2010
1	Transcription Factors (Transcription Factor)IBA 10/2009
1	4-S-(propionic acid)sulfidocyclophosphamide (PASP)IBA 10/2009
1	hydroxide ionIBA 10/2009
1	cyclo(Arg-Pro) (CI 4)IBA 10/2009
1	Sucrose (Saccharose)IBA 10/2009
1	ArginaseIBA 01/2009
1	Hypoxia-Inducible Factor 1IBA 01/2008
1	Butylated Hydroxyanisole (BHA)IBA 01/2008
1	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 01/2005
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2005
1	TensinsIBA 01/2005
1	CatecholaminesIBA 06/2003
1	Adrenergic Agents (Adrenergic Drugs)IBA 06/2003
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 06/2003
1	Protein Isoforms (Isoforms)IBA 06/2003

Therapy/Procedure

1	Intravenous Infusions 10/2009
1	Aftercare (After-Treatment) 08/2008